The sensitivity and specificity of the primary and secondary antibodies used together with the IHC procedure used, are critical to avoid biased results. Several factors can cause false-positive or false-negative data, so they should all be verified as much as possible for each experimental set-up.
Here, let’s look at 3 tips that will be of help to improve your IHC data.
A recent publication by ArrayBridge, Inc., in cooperation with Wayne State University, focuses on monoclonal antibody (mAb) Higher Order Structure Analysis.
The clinical and biological properties of protein-based therapeutics, or biologics, are closely related to their Higher Order Structures (HOS), which in turn can be altered by many physical and chemical conditions. The paper describes a novel technology to monitor changes in mAb HOS – the Protein Conformational Array (PCA) ELISA – which is based on a unique bank of more than 30 well-characterized antibodies enabling the measurement of protein epitope change on the surface of the mAb.
The use of validated antibodies are primordial for Breast Cancer research. Let’s see why, and which were the most popular ones in 2015.
Breast cancer arises in cell units whose function is to secrete milk, ducto-lobular breast units, mainly in women, with 89 cases per 100 000 (1). 5 to 10% of these cancers have an inherited genetic origin; 85-90% of cases (known as sporadic or non-hereditary) have environmental origins as yet often unidentified. A significant proportion of sporadic breast cancers is induced by hormonal treatment in women with a predisposition to this type of cancer. Some lifestyle choices (alcohol, trans fats, obesity, lack of exercise) or gynecological (late first pregnancy, not breastfeeding, etc.) also promote cancer.
If detected at an early stage, this cancer can be cured in 9 cases out of 10. Nevertheless, one of the difficulties of curing this disease is to identify the biological characteristics of each patient’s tumor.